# Buprenorphine + Naloxone

## Suboxone 8/2mg

| TAH Drug Code      | [**OSUB**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OSUB)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of opioid dependence.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | Adults and teenagers over 15 years old: Day 1 induction dose: Initial: Buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg sublingual; may increase the dose with buprenorphine 2 to 4 mg/naloxone 0.5 to 1 mg, based on control of acute withdrawal symptoms. Adjust and maintain dose: Titrate the dose with buprenorphine 2 to 8 mg based on patient's clinical and psychological status(Max:buprenorphine 24mg/day). Heroin or short-acting opioid dependency: Start treatment when withdrawal symptoms occur, but 6 hours after patient takes the last opiods. For patients taking methadone: Patients taking methadone > 30mg/day should start the treatment from Buprenorphine 2 mg/naloxone 0.5 mg and mind the half-life of methadone. Start treatment when withdrawal symptoms occur, but 24 hours after patient takes the last dose of methadone. Buprenorphine may increase withdrawal symptoms of methadone. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity to buprenorphine, naloxone, or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Central nervous system: Headache (36%), withdrawal syndrome (25%; placebo 37%), pain (22%) Dermatologic: Diaphoresis (14%) Gastrointestinal: Glossodynia (film), oral hypoesthesia (film), oral mucosa erythema (film)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Pregnancy          | No (Limited) Human Data â€“ Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

